The FDA has updated guidance on compounded GLP-1 drugs, documenting specific quality and fraud problems that have reached patients — including medications arriving warm and vials labeled with pharmacies that do not exist. The update also highlights an existing import alert that continues to target substandard active pharmaceutical ingredients at the U.S. border.
The agency’s import alert for GLP-1 ingredients, identified as Import Alert 66-80 and sometimes referred to as the “Green List,” was established in September 2025 and remains active. It was not newly created this week. The alert is designed to stop substandard ingredients from entering the U.S. supply chain while allowing importation from manufacturers that meet FDA standards.
What is new is updated FDA guidance documenting problems in the compounded GLP-1 market, including semaglutide and tirzepatide products. According to the agency, issues have reached patients directly, with reports of compounded medications arriving warm and vials carrying labels from pharmacies that do not exist.
What happened
The FDA’s import alert covering GLP-1 active pharmaceutical ingredients was established in September 2025 under Import Alert 66-80. The alert functions as a border enforcement mechanism, allowing FDA staff to detain shipments of GLP-1 ingredients from manufacturers that do not meet agency quality standards while permitting entry from those that do.
The updated guidance published this week documents specific problems in the compounded GLP-1 supply chain. The guidance describes compounded medications arriving at patients’ doors warm, and vials labeled with the names of pharmacies that do not exist, pointing to fraudulent labeling practices.
Separate reporting indicates the FDA is tracking hundreds of reports tied to compounded weight-loss drugs and unapproved peptides.
Why it matters
The import alert represents a concrete supply-chain enforcement action that goes beyond warning letters, targeting the raw-material source of potentially unsafe compounded GLP-1 drugs. By screening API imports, the FDA aims to prevent substandard ingredients from reaching compounding pharmacies and, ultimately, patients.
The fraudulent labeling guidance addresses a specific patient-harm vector. Vials labeled with nonexistent pharmacies make it difficult or impossible for patients, providers, and regulators to trace products back to a responsible facility. For compounding pharmacies, telehealth platforms prescribing GLP-1s, and 503B outsourcing facilities, the guidance signals that labeling and supply-chain integrity should be audited immediately.
Affected groups include compounding pharmacies, telehealth platforms, 503B outsourcing facilities, API importers, and patients using compounded weight-loss drugs.
What to watch next
- Whether the FDA expands the import alert to cover additional manufacturers or ingredient types
- How compounding pharmacies and telehealth platforms respond to the fraudulent labeling concerns
- Whether further enforcement actions, such as warning letters or seizures, follow the guidance update
- Additional details on the hundreds of reports the FDA is tracking tied to compounded weight-loss drugs and unapproved peptides
Sources
Industry information only. Not medical or legal advice.
